U.S. regulators have warned Johnson & Johnson unit Janssen Pharmaceutica that a letter sent to doctors about its Risperdal drug to treat schizophrenia and bipolar mania is misleading. In a warning disclosed on Tuesday, the Food and Drug Administration told Janssen that its November letter failed to disclose information added to Risperdal’s labeling about excess blood sugar and diabetes and minimized the risk of serious events including coma and even death. The FDA also said the letter fails to recommend regular testing for diabetes and “misleadingly claims that Risperdal is safer than other atypical antipsychotics.”

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 27 Apr 2004
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2004). J&J Warned on Claims About Antipsychotic Drug. Psych Central. Retrieved on November 1, 2014, from http://psychcentral.com/blog/archives/2004/04/27/jj-warned-on-claims-about-antipsychotic-drug/

 

Recent Comments
  • scrutinize,anylize,contrast: Psychologists, Psychiatrists, MFC’s, LSW,well, they’ll all human. I have had...
  • Paula: ” Things like shooting without looking through the viewfinder” I don’t understand this.
  • Cindy: I have been going through pain for about three years now. I have asked for help with this for three years. I...
  • thatjournalistdork: I agree that the use of “said” does get boring and annoying, but it is proper AP...
  • lisa: I am at a loss,my baby sister who is smart,and loving phoned me one day and starting crying,I hope that I was...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code